IP Library Patent Application 15211074
Patent Application
App. No. 15/211,074

METHOD OF TREATING THERMOREGULATORY DYSFUNCTION WITH PAROXETINE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/211,074
Abstract

The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the hot flashes, hot flushes, or night sweats associated with disease states that disrupt normal hormonal regulation of body temperature.

Claims (12)

1 . A method for treating a patient suffering from a thermoregulatory dysfunction comprising administering to said patient a compound selected from paroxetine, a pharmaceutically acceptable salt thereof, a hydrate or solvate of either, in any polymorphic form, and mixtures thereof; said compound being in an amount, based on the paroxetine moiety, which is at least about 0.1 mg/day up to less than a therapeutically effective antidepressant dosage of paroxetine.

2 . The method of claim 1 wherein said compound is administered in an amount of at least 0.5 mg/day.

3 . The method of claim 1 wherein said compound is administered in an amount of at least 1 mg/day.

4 . The method of claim 1 wherein said compound is administered in an amount of at least 2 mg/day.

5 . The method of claim 1 wherein said compound is administered in an amount of at least 4 mg/day.

6 . The method of claim 1 wherein said compound is administered in an amount of not more than about 9.5 mg/day.

7 . The method of claim 1 wherein said compound is administered in an amount of not more than about 9 mg/day.

8 . The method of claim 1 wherein said compound is administered in an amount of not more than about 8.5 mg/day.

9 . The method of claim 1 wherein said compound is administered in an amount of not more than about 8 mg/day.

10 . The method of claim 1 wherein said compound is administered in an amount selected from 2 mg/day, 2.5 mg/day, 3 mg/day, 3.5 mg/day, 4 mg/day, 4.5 mg/day, 5 mg/day, 5.5 mg/day, 6 mg/day, 6.5 mg/day, 7 mg/day, 7.5 mg/day, 8 mg/day, and 8.5 mg/day.

11 . The method of claim 1 wherein said thermoregulatory dysfunction is the result of a condition selected from female menopausal related hormonal changes, male menopausal related hormonal changes, chemically induced hormonal changes, surgically induced hormonal changes, hormonal disruption disease states, and any combination thereof.

12 . The method of claim 1 wherein said therrnoregulatory dysfunction is a condition selected from the group consisting of hot flashes, hot flushes, night sweats and combinations thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 30, 2018
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
To: SEBELA INTERNATIONAL LIMITED
Reel/Frame 045190/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2016
From: NOVEN PHARMACEUTICALS, INC.; NOVEN THERAPEUTICS, LLC
To: SEBELA INTERNATIONAL LIMITED
Reel/Frame 039334/0114 →
SECURITY INTEREST Recorded Jul 26, 2016
From: SEBELA INTERNATIONAL LIMITED
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 039260/0962 →